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Abstract: Background: The blood brain barrier (BBB) is a dynamic and functional structure which
poses a vast challenge in the development of drugs acting on the central nervous system (CNS).
While most substances are denied BBB crossing, selective penetration of substances mainly occurs
through diffusion, carrier mediated transport, or receptor mediated transcytosis. Methods: Strategies
in enhancing BBB penetration have been reviewed and summarized in accordance with their type
of formulation. Highlights in monoclonal antibodies, peptide-vectors, nanoparticles, and simple
prodrugs were included. Conclusion: Nanoparticles and simple prodrugs, for example, can be used for
efficient BBB penetration through inhibition of efflux mechanisms, however, monoclonal antibodies
are the most promising strategy in BBB penetration. Close follow-up of future development in this
area should confirm our expectation.
Keywords: blood brain barrier; drug penetration strategies; monoclonal antibody; peptide-vector;
nanoparticles; prodrugs
1. Introduction
The blood brain barrier (BBB) is a structural and functional barrier which protects and maintains
a highly controlled environment for central nervous system (CNS) neurons. The BBB lines brain and
spinal cord capillaries with endothelial cells, astrocytes, pericytes, microglia, and muscle cells. The cells
are connected by tight junctions and express a variety of receptors, transporters, and pores which allow
for penetration of specific substances from the blood into the CNS. BBB tight junctions are formed by
junctional adhesion molecules, occludin and claudin, and transmembrane proteins [1]. Transport across
the BBB can be achieved by the transcellular and paracellular pathways. Lipophilic agents are usually
transported via transcellular pathways, while hydrophilic molecules cross via paracellular pathways.
Paracellular pathways are regulated by tight junctions. Reversibly opening paracellular pathways
through antisense oligonucleotides and siRNA or tight junction targeting by toxins and proteins has
previously been reported [2,3].
It is estimated that more than 98% of small molecule drugs and approximately 100% of large
molecule drugs do not cross the BBB [4,5]. Consequently, the BBB plays a pivotal role in minimizing CNS
toxin exposure, controlling immune–CNS communication, maintaining a low protein CNS environment,
separating peripheral and CNS neuro-signals, and importantly, regulating ion homeostasis [6].
BBB Transport Routes
In healthy individuals, substances have been found to cross the BBB through many pathways.
The most common pathways are the following:
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A: Transmembrane diffusion
The majority of compounds cross the BBB via this mechanism [7]. While it is nonsaturable,
it depends significantly on drug physico-chemical properties, such as low molecular weight, and
lipid solubility. While higher lipid solubility leads to better BBB penetration [8], it also leads to an
unfavorable increase in oxidative metabolism and volume of distribution [8]. Therefore, the effects of
increasing lipophilicity on BBB penetration must be balanced in light of membrane permeability and
metabolism [9,10]. Lipid solubility is affected by several factors, such as charge, protein binding, and
most importantly, molecular weight, which is rarely above 500–600 Da [11].
B: Carrier mediated transport: Influx and efflux
A large variety of transporters are present at the BBB; including influx transporters such as l-type
amino acid transporter (LAT1), glucose transporter (GLUT1), monocarboxylate lactate transporter
(MCT1), cationic amino acid transporter (CAT1), choline transporter (ChT), sodium-coupled glucose
transporters (SGLTs), among others. Examples of efflux transporters include p-glycoprotein (P-gp),
peptide transport system-6 (PTS-6), and breast cancer resistant protein (BCRP) [12–15]. While influx
transporters enhance substance uptake by BBB, efflux transporters retard it. Transporters can also
be energy dependent, such as P-gp, or energy independent, such as GLUT1. Transporter-mediated
uptake is roughly 10-fold faster than trans-membrane diffusion [16] and can be utilized by either efflux
inhibition or influx substrates to enhance drug delivery to the CNS.
C: Transcytosis
The most common type of transcytosis is receptor-mediated transcytosis. Several receptor
transporters and their role in substance transport across the BBB have been identified. Insulin receptor
(IR) provided the answer to how insulin can be found in abundance in the brain while there is no
insulin mRNA in the brain [17]. Transferrin receptor (TfR) mediates the transport of iron from the blood
across the BBB and apo-transferrin from the brain to the blood [18,19]. Many other receptors have
also been located, such as low-density lipoprotein receptor (LDLR), neonatal Fc receptor (FcRn) [20],
and leptin receptor (LepR) [21].
D: Nasal delivery
Also, intranasal delivery offers approaches to more direct and efficient drug delivery.
Nasally administered drugs can reach the brain through direct or indirect pathways. Direct ones,
i.e., the trigeminal nerve pathway and the olfactory mucosa pathway, offer approaches by which a
hepatic first pass metabolism is potentially avoided as well as a direct diffusion into the brain. Indirect
pathways involve the drug reaching the respiratory tract and circulating through the blood to reach the
BBB classically. Although a small portion of the drug can eventually reach the brain (due to mucociliary
clearance for example), intranasal delivery could provide answers to drug delivery to the brain [22–24].
Drugs capable of crossing BBB have been on the market for decades and are well-known.
Such drugs include L-DOPA, the metabolic precursor of dopamine, which crosses assisted by
LAT1 [25]. Similarly, melphalan [26] and gabapentin [27] are substrates for LAT1 and cross through
receptor-mediated endocytosis. This is due to their chemical structures mimicking that of large amino
acids, like tyrosine for example, consisting of a branching structure with an amino group, a carboxyl
group, and a hydrophobic side chain (Figure 1).
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for multiple sclerosis [29], edaravone for amyotrophic lateral sclerosis [30], and valbenazine for 
tardive dyskinesia [31] (Figure 2). However, available treatments for neurodegenerative and CNS 
disorders are far from optimal. Major drawbacks from which current treatments suffer include 
peripheral metabolism and instability leading to the need of high doses, as well as BBB efflux and 
denied penetration. Many strategies are being employed to overcome the BBB penetration barrier in 
an attempt to potentiate treatments for those conditions. In this review, we highlight monoclonal 
antibodies, peptide-vectors, nanoparticles, and simple prodrugs as strategies for enhancing BBB 
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Figure 1. Chemical structures of tyrosine (an amino acid, LAT1 substrate), L-DOPA, Melphalan,
and Gabapentin.
Moreover, new agents for brain targeted delivery are also being granted FDA approval.
Recent examples include cariprazine and brexpiprazole for schizophrenia [28], daclizumab and
ocrelizumab for multiple sclerosis [29], edaravone for amyotrophic lateral sclerosis [30], and
valbenazine for tardive dyskinesia [31] (Figure 2). However, available treatments for neurodegenerative
and CNS disorders are far from optimal. Major drawbacks from which current treatments suffer
include peripheral metabolism and instability leading to the need of high doses, as well as BBB
efflux and denied penetration. Many strategies are being employed to overcome the BBB penetration
barrier in an attempt to potentiate treatments for those conditions. In this review, we highlight
monoclonal antibodies, peptide-vectors, nanoparticles, and simple prodrugs as strategies for enhancing
BBB penetration.
Molecules 2018, 23, 1289 4 of 18
Molecules 2018, 23, x 4 of 18 
 
 
Figure 2. Chemical structures of cariprazine, brexpiprazole, edaravone, and valbenazine. 
2. Drug Delivery Strategies 
2.1. Monoclonal Antibody Strategy 
While the BBB prevents penetration of the majority of arriving substances, it selectively allows 
others. As previously mentioned, endogenous substances such as insulin, iron, LDLs, and others are 
substrates for carriers located at the BBB which facilitate their penetration into the CNS. Therefore, 
formulation of receptor-targeted monoclonal antibodies (MAbs) is being utilized to increase 
penetration across the BBB. 
Targeting of insulin receptors can be done using insulin, though this will lead to hypoglycaemia, 
therefore, monoclonal antibodies against human insulin receptors were developed. Pardridge et al. 
[32] developed a human insulin receptor monoclonal antibody (HIRMAb) with high affinity binding 
to IR (KD = 1.2 nM). Then, the extent to which this MAb could act in drug delivery was tested [33]. 
Biotnyl[125I]-Aβ1-40 (amyloid beta) was bound to the MAb and streptavidin. While film 
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Also, HIRMAb fusion proteins were synthesized. Iduronidase (IDUA) enzyme can be used for 
the treatment of mucopolysaccharidosis type I (MPSI) though it does not cross the BBB. HIRMAb-
IDUA enables enzyme replacement therapy by increasing BBB penetration [34–36]. The fusion 
protein AGT-181 had brain uptake of 1% ID/brain and fusion protein activity in brain predicts that 
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2. Drug Delivery Strategies
2.1. Monoclonal Antibody Strategy
While the BBB prevents penetration of the majority of arriving substances, it selectively
allows others. As previously mentioned, endogenous substances such as insulin, iron, LDLs, and
others are substrates for carriers located at the BBB which facilitate their penetration into the CNS.
Therefore, formulation of receptor-targeted monoclonal antibodies (MAbs) is being utilized to increase
penetration across the BBB.
Targeting of insulin receptor can be done usi g insulin, th ugh this wil lea to hypo lycaemia,
therefor , m noclonal antibodies against human insulin receptors were developed. P rdridge et al. [32]
developed a human insulin r c ptor mono lonal anti ody (HIRMAb) with high affinity binding
to IR (KD = 1.2 nM). Then, the extent t which this could act in rug delivery was
tested [33]. Biotnyl[125I]-Aβ1-40 (amyloid beta) was bound to the MAb and streptavidin. While film
autoradiography deter ined that Aβ1-40 does not cross BBB, the drug-biological conjugate exhibited
high brain uptake comparable to that of small molecules.
Also, HIRMAb fusion proteins were synthesized. Iduronidase (IDUA) enzyme can be used for the
treatment of mucopolysaccharidosis type I (MPSI) though it does not cross the BBB. HIRMAb-IDUA
enables enzyme replacement therapy by increasing BBB penetration [34–36]. The fusion protein
AGT-181 had brain uptake of 1% ID/brain and fusion protein activity in brain predicts that an infusion
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dose of 1 mg/kg should restore enzyme activity to human brain. AGT-181 is currently in clinical trials
for the treatment of Hurler syndrome in children; with reported treatment duration of 6 months [37].
OX26 MAb is a substrate of rat and human transferrin receptor (TfR), the reason behind its
original discovery [38]. In mouse, OX26 was also found to have potential in delivering agents into
mouse brain [39]. OX26 in humans was used to deliver agents across the BBB by TfR targeting such as
vasoactive intestinal peptide (VIP) [40].
Bispecific antibodies (bsAb) are novel molecules with two different binding sites [24].
These molecules are still in development as BBB penetration enhancers. Recent attempts include
a bsAb with TfR and BACE1 binding sites. The resulting bsAbs exhibited contrasting results due to
their binding affinities to TfR. Low affinity binding to TfR resulted in increased BACE1 BBB penetration
while high affinity resulted in poor penetration [24,41].
Low-density lipoprotein receptor-related protein 1 (LRP1) is another target for MAb since it is
responsible for the transport of several ligands across the BBB [42–44]. ANG-1005, a conjugate between
paclitaxel and Angiopep-2, was synthesized (Figure 3) [45]. Angiopep-2 is a derived peptide and a
ligand for LRP1 [46]. Conjugated paclitaxel demonstrated significant improvement in BBB penetration
vs. unconjugated paclitaxel.
Brain derived neurotrophic factor (BDNF) can be used post stroke or brain injury to provide
neuroprotection and prevent neuronal death [47]. BDNF chimeric peptide was conjugated to TfRMAb
through an SA-biotin linkage. The BDNF end of the peptide exerts its action on tropomyosin receptor
kinase B (TRKB) receptors in the CNS for neuroprotection following brain injury while the MAb allows
for targeted transport from the blood [48,49]. Hence, the resulting agent combines the monoclonal
antibody strategy and the following peptide-vector strategy.
While the MAb strategy potentially has the ability to produce major BBB penetrating agents,
it still, suffers from drawbacks [50]. Monoclonal antibodies targeted at specific carriers will interfere
with ligand transfer, such as insulin or iron, depending on the affinity of that MAb. This drawback is
expected to have worse effects as the dose of the administered agent is increased. Furthermore, immune
reactions to biologic drugs have previously been reported in practice [51].
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2.2. Peptide-Vector Strategy 
Large molecules such as peptides suffer from diminished BBB penetration and efflux and thus 
need to be injected into the cerebrospinal fluid (CSF) if they are to be used therapeutically. 
Nevertheless, certain peptides can be used as P-gp inhibitors to ease the penetration of other agents. 
In a work by Rouselle et al. [52] antineoplastic doxorubicin (dox) was coupled to D-penetrin and 
SynB1, respectively, to enhance delivery of dox to brain (Figure 4). Dox BBB penetration was studied 
in rat brain perfusion is situ and by IV injection in mice. The team demonstrated that this technique 
resulted in a 6-fold increase in dox penetration as free dox exhibited very low uptake due to P-gp 
efflux while vectorized dox was able to bypass it. 
Figure 3. A schematic representation of ANG-1005, a conjugate between paclitaxel and Angiopep-2.
2.2. Peptide-Vector Strategy
Large molecules such as peptides suffer from diminished BBB penetration and efflux and
thus need to be injected into the cerebrospinal fluid (CSF) if they are to be used therapeutically.
Nevertheless, certain peptides can be used as P-gp inhibitors to ease the penetration of other agents.
In a work by Rouselle et al. [52] antineoplastic doxorubicin (dox) was coupled to D-penetrin and
SynB1, respectively, to enhance delivery of dox to brain (Figure 4). Dox BBB penetration was studied
in rat brain perfusion is situ and by IV injection in mice. The team demonstrated that this technique
resulted in a 6-fold increase in dox penetration as free dox exhibited very low uptake due to P-gp
efflux while vectorized dox was able to bypass it.
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Cultured neurons show that Rabies virus glycoprotein (RVG) is likely to cross the BBB through
nicotinic acetylcholine receptors [53], though it does not bind to nucleic acids, and hence, is incapable
of li ring siRNA. In a work by Kumar et al. [54], small interference RNA was transduced using
derived RVG-9 . Specific gene silencing was achieved in mice providing protection against viral
encephalitis. R sults how that RVG-9R provides safe means for delivery f siRNA across the BBB.
Other peptides, such as the highly cationic peptide HIV trans-activator of transcription (TAT),
were studied as possible BBB penetration enhancers. Though, while TAT’s in vitr uptake is
enhanced, results still reflect negatively on its role in vivo [55,56]. Insulin-like growth factor
2 (IGF2) is also a peptide with high affinity to insulin-like growth factor receptors at the human
BBB, although it suffers from high protein binding (>99%) in the blood and thus has proved
impractical, as of yet, as a permeability enhancer. This was demonstrated in a fusion protein of
N-acetyl-alpha-glucosaminidase-IGF2 (NAGLU-IGF2) [57].
2.3. Nanoparticles
Due to great potential that nanoparticles (NPs) possess, such as surface functionalization and
decoration, size variance, drug loading capacity, immune-compatibility, and others, their applications
are being investigated in several fields [58–60]. They can be organic, such as liposomes, or solid lipid
NPs, or inorganic, such as gold or silver NPs.
B6 is a peptide sequence with affinity for TfR receptors with potential to mediate delivery across
BBB [61]. Liu et al. [62] have conjugated B6 to poly(ethylene glycol)-poly(lactic acid) (PEG-PLA) NPs
to allow for increased penetration and demonstrated that B6 actually plays part in cellular uptake in
mouse endothelial cells.
Kim et al. [63] used chitosan NPs targeted for BBB penetration through RVG conjugation.
The pluronic-based nanocarriers in combination with RVG pe tide and chit san proved efficient
in increasing BBB penetration substantially while maintaining activity of the tested delivered protein.
Mittal et al. [64] designed rasagiline chitosan glutamate nanoparticles. By comparing intranasal
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delivery, free drug solution, and IV delivery, the authors achieved significantly higher concentrations
in brain following intranasal delivery.
Cheng et al. [65] tested gold NPs’ (AuNPs) ability to cross endothelial and brain tumour cells. Two types
of NPs were decorated, one with TAT and another with PEG as stealth and uptake enhancers. TAT NPs
exhibited markedly better penetration. AuNPs-TAT-Dox was successfully delivered in tumour-implanted
mice and prevented premature death or body weight loss. Similarly, Clark and Davis [66] prepared
transferrin bearing AuNPs. Transferrin was linked to the AuNPs using a linker cleavable in acidic conditions
resulting in a threefold increase in BBB penetration. Silver NPs (AgNPs), on the other hand, have been found
to cause concentration-dependent BBB inflammation and cytotoxicity [67], and are, therefore, unsuitable
carriers for BBB penetration.
Liposomes are multi-layered spherical lipid particles which encapsulate an aqueous compartment.
While the inner compartment can be used to deliver payloads, the outer lipid layers provide a shield
before reaching the target site as well as sites to load lipophilic drugs. Moreover, the lipid layers can be
conjugated with targeting molecules or carriers to specifically and efficiently reach the site of action, or
in these cases, facilitate BBB penetration. In a study by Salvati et al. [68], an anti-transferrin receptor
antibody (RI7217) was conjugated to the surface of liposomes to facilitate BBB entry. The liposomes
were fluorescent and composed of sphingomyelin and cholesterol known to bind to amyloid-β.
Immunoblotting revealed that the liposomes bound to TfR had higher permeability in comparison to
non-decorated liposomes.
In a study by Li et al. [69], transferrin-bound carbon dots loaded with doxorubicin were
synthesized. Carbon dots are a new type of biocompatible nanoparticles with unique properties [70].
Synthesized nanoparticles were composed of a carbon dot core unto which dox and transferrin were
bound via carboxylic groups (CD-dox). Their efficacy was investigated in four pediatric cell lines with
over-expressed TfR (CHLA-266, SJGBM2, CHLA-200, Daoy). The investigators report greater efficacy
of the NPs, reducing viability by 14–45% when compared to dox alone.
The application of single walled carbon nanotubes (SWCNTs) has been studied in several
areas of medicine as drug carriers, in neuro-regeneration [71], cancer, and biomedical sensors [72].
Tan et al. [73] have studied the toxicity and potential application of SWCNTs as carriers for levodopa.
Results reported show that SWCNT-COOH particles exhibited sustained-release of LD over more
than 20 h. Furthermore, the SWCNT-COOH-LD nanohybrid was pH activated. Importantly, cell
viability was not compromised even after 72 h after treatment with the NPs. Similarly, in a recent
work by Guo et al. [74], SWCNTs functionalized with lactoferrin and PEG were tested as carriers for
dopamine delivery in mice. PEG coating increased stability and circulation time of the NPs while
lactoferrin allowed for increased accumulation in striatum. The resulting SWCNT-PEG-Lf particles
exhibit favourable properties for dopamine delivery to brain.
Other carbon nanoparticles such as Fullerenes are being explored [75,76]. Fullerenes are spherical
C60 particles with unique geometrical shape. Though they possess unique photo-physical and
antioxidant properties, their application is limited due to poor solubility in polar solvents—notably
water. Therefore, conjugation of fullerenes to molecules with affinity to receptors, proteins, organelles,
etc. . . . is crucial to their biological application. In a work by Tsao et al. [77], carboxyfullerene 20 was
tested on twenty different bacterial strains. Under specific conditions, BBB permeability of E. coli
responsible for causing meningitis was diminished. It appeared that carboxyfullerenes inhibited
cytokines and other factors released by neutrophils which alter BBB permeability.
Bi et al. [78] investigated the ability of PEG-poly(lactic co-glycolic acid) (PEG-PLGA)
biodegradable nanoparticles to provide efficient delivery of rotigotine to brain via nasal administration.
The NPs were spherical with narrow size distribution and negative potential. Two types of NPs were
prepared: non-surface modified rotigotine NPs, and rotigotine surface-modified with lactoferrin (Lf).
Surface modified NPs had a size of 160 nm while unmodified rotigotine NPs were 100 nm. In vitro
toxicity of the NPs was found to be low and cellular uptake was enhanced in Lf modified NPs.
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Intracellular adhesion molecule 1 (ICAM-1) is a transmembrane protein expressed on cells in
lysosomal disorders. Pathological factors such as oxidative stress, inflammation, and metabolic
imbalance, which are characteristic of lysosomal disorders, are high up regulators of ICAM-1
expression [79]. Several works exploring targeting of ICAM-1 have been reported in the literature [80,81].
In a work by Garancho and Muro [82], polymer nanocarriers coated with ICAM-1 targeting peptide
were examined. Prepared nanocarriers were endocytosed and trafficked to lysosomes, restoring levels
of sphingomyelin and cholesterol within lysosomes. The authors state that the fibrinogen-derived
ICAM-1 targeting peptide used in the study holds potential for lysosomal enzyme therapy.
2.4. Simple Prodrug Strategy
Prodrugs are molecules which upon their chemical or enzymatic activation result in an active and
intended drug. This strategy has been applied widely throughout medicine in improving drug
profiles and delivery [83–85]. Although research has taken a trend towards nanomedicine and
biologicals in recent years, this strategy still can be exploited in BBB penetration due to its simplicity
and vast potential.
In dopamine delivery, several prodrugs have been previously synthesized and aimed
towards increased BBB penetration. Denora et al. [86] have succeeded in preparing a series
of 2-phenyl-imidazopyridine-3-acetic acid substituted dopamine compounds which maintained
peripheral dopamine stability while enhancing CNS delivery.
Due to the fact that glycosylated derivatives of drugs have the ability to increase CNS uptake
by GLUT1, Fernandez et al. [87,88] have synthesized several glycosylated derivatives of dopamine
using several linkers to enhance dopamine BBB penetration (Figure 5A). They report that of the
derivatives tested those with conjugates substituted at C-6 were much more potent inhibitors. Ester
derivatives were found too unstable in the plasma while carbamate derivatives are the prodrugs of
choice. In works by Bonina et al. [89] and Ruocco et al. [90], the authors attached dopamine to glucose
C-3 and C-6 also targeting GLUT1 with favourable activity when compared to L-DOPA (Figure 5B).
Glutathione conjugated prodrugs of dopamine were synthesized by More and Vince [91] (Figure 6)
targeting BBB glutathione transporters. Their prodrugs constituted dopamine connected to glutathione
as a carrier through a variety of linkages of which amide was found to have high affinity to BBB
glutathione transporters.
In a work by Dalpiaz et al. [92], ursodeoxycholic acid (UDCA) was used to increase the
permeability of azidothymidine (AZT) into CNS using a simple ester prodrug (Figure 7). The 5′-ester
conjugate of AZT with UDCA was able to bypass CNS efflux and deliver up to twenty times more of
AZT to CNS macrophages. Permeability studies were carried out on HRPE cellular monolayer.
Gynther et al. [93] synthesized an ester prodrug of ketoprofen and L-tyrosine (Figure 8) to deliver
hydrophilic ketoprofen to CNS through LAT1. The authors tested for LAT1 binding using radiotracer
[14C] L-leucine showing that their prodrug provided marked inhibition of tracer uptake. The ester
prodrug was able to reach brain parenchyma, although the authors stated that the ester linkage present
would most likely to be broken by periphery esterase.
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Glucose and galactose esters of 7-chlorokynurenic acid were synthesized by Battaglia et al. [94]
(Figure 9) to facilitate BBB penetration through GLUT1 transporters. Following intraperitoneal injection,
the delivered drug was found to have increased anti-seizure activity due to enhanced penetration.
The authors state that this prodrug would be expected to undergo extensive hepatic metabolism if it
were to be administered orally.
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Anti-HIV drugs are good P-gp substrates and are extensively denied BBB entry. Prodrug dimers
were designed with P-gp inhibition in mind to increase abacavir BBB penetration. Namanja et al. [95]
linked two molecules of abacavir using sulphide and ester linkages which would be removed
intracellularly. The resulting dimer was shown to have P-gp inhibitory action resulting in increased
BBB penetration [96]. Linking two identical or different P-gp substrates through simple linkages is of
great potential since it can allow for dual-drug delivery or selective P-gp inhibition through an inactive
substrate while the desired drug is granted BBB entry.
The following Table 1 summarizes select strategies reported in this review.
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Table 1. Select works in improving CNS penetration reported in this review.
Strategy Tested Agent Notes Future Outlook Ref.
Human insulin receptor
monoclonal antibody None
High affinity and
high transcytosis.
Further investigation
and optimization. [33,34]
Human insulin receptor
monoclonal antibody
Iduronidase & IGG
fusion protein
Clinical trials for Hurler
syndrome in children. Further results from trial. [38]
Bispecific antibody TfR and BACE1binding sites
Application of dual
action antibodies.
Research of binding
site combinations. [42]
Peptide vectorization Doxorubicin with
D-penetrin or SynB1
6-fold increase in
doxorubicin permeation.
D-penetrin or SybB1 can both
be used as BBB targeting
entities for other drugs.
[53]
Transferrin decorated
carbon dots Doxorubicin
Greater efficacy vs free
doxorubicin in 4 pediatric
cell lines.
Drugs other than doxorubicin
can be tested. [70]
Single walled carbon
nanotubes Levodopa
Sustained release properties
with low toxicity.
Application as drug carriers
in BBB penetration. [74]
Single walled carbon
nanotubes coated with
PEG and functionalized
with lactoferrin
Dopamine
PEG coating increases stability
of the NPs while lactoferrin
produces favorable
striatum accumulation
Testing in mice is promising.
Further toxicity and kinetics
studies before human
application is tested.
[75]
Carboxyfullerene NPs None
Interaction and inhibition
with inflammatory factors
maintains BBB integrity.
Fullerenes are unexplored
with vast potential should
solubility be overcome.
[78]
PEG-poly(lactic
co-glycolic acid) NPs
surface modified
with lactoferrin
None
Administration intranasally
for CNS delivery. Low toxicity
and enhanced cellular uptake.
Lactoferrin modification of
NPs for CNS delivery. [79]
Glycosylated derivatives
of L-DOPA prodrugs L-DOPA
Carbamate derivatives are
more stable than ester ones.
Glycosylated derivatives at
C-6 is better than C-3.
Glycosylation at C-6 provides
better inhibition and uptake
through GLUT-1
[88–91]
Dimer prodrug Abacavir
Sulphide and ester linkages
between two P-gp substrates
increases BBB penetration.
Two identical or different
P-gp substrates allows for
dual-drug delivery.
[96]
3. Summary and Conclusions
Recent strategies can be categorized into monoclonal antibodies, peptide vectors, nanoparticles,
and simple prodrugs (select works are reported in Table 1 above). Monoclonal antibodies possess
significant potential, not only in BBB penetration but in other areas of drug design as well.
Although, since they are tailored to match very specific sites, they tend to be quite tricky to design,
thus hindering their discovery. In BBB penetration though, the recently approved daclizumab and
ocrelizumab reflect the potential of this strategy, but, nevertheless, warrant close future follow-up to
pass judgment on the success of this strategy.
Peptide vectors, we believe, are the least promising of the strategies mentioned in this review.
While peptides are good substrates for BBB transporters, the design and synthesis of peptides alone is
challenging, and those with loaded active agents and controlled release are especially much harder and
time consuming to deal with. When it comes to complexity, both the peptide vectors and monoclonal
antibodies are similarly complex to design, though the latter are clearly superior when it comes to
BBB penetration.
Nanoparticles on the other hand, possess huge potential in BBB penetration as they do in other
fields. Due to the vast types of possible nanoparticles, which can be organic or inorganic, surface
decorated or not, bound to peptides or not, targeted or not, with one drug molecule or more, they
appear to be the future of modern therapy though still far from complete. Nanoparticles rely on the
continuous discovery and optimisation of drugs.
Simple prodrugs, such as esters, still are possible contenders in BBB penetration. Dimers are of
interest since they combine P-gp inhibition and delivery in one molecule. Though those reported in
the review use two identical molecules, dimers can be used in combining two complimentary agents,
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or perhaps three. Alas, similar to nanoparticles, the design of prodrugs relies on the existence of the
original drug, also making them dependent on the continuous delivery of active drugs.
To conclude, and due to the continuous discovery of CNS active agents, it is obvious that BBB
penetration is not the hardest of tasks facing drug designers nowadays. With strategies such as
those highlighted in the review, and with the optimal agents, CNS drug delivery should produce a
breakthrough within the upcoming decade.
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BBB Blood brain barrier
CNS Central nervous system
LAT1 L-type amino acid transporter 1
GLUT1 Glucose transporter 1
MCT1 Monocarboxylate transporter 1
CAT1 Cationic amino acid transporter 1
ChT Choline transporter
SGLT Sodium-coupled glucose transporter
P-gp P-glycoprotein
PTS-6 Peptide transport system 6
BCRP Breast cancer resistant protein
IR Insulin receptor
Tf Transferrin
TfR Transferrin receptor
LDLR Low-density lipoprotein receptor
FcRn Neonatal Fc receptor
LEPR Leptin receptor
MAb Monoclonal antibody
IDUA Iduronidase
MPSI Mucopolysaccharidosis type I
bsAb Bispecific antibodies
LRP1 Low-density lipoprotein receptor related protein 1
BDNF Brain derived neurotrophic factor
TRKB Tropomyosin receptor kinase B
CSF Cerebrospinal fluid
Dox Doxorubicin
RVG Rabies virus glycoprotein
TAT Trans-activator of transcription
IGF2 Insulin-like growth factor 2
NAGLU N-acetyl-alpha-glucosaminidase
NP Nanoparticle
PEG Poly (ethylene glycol)
PLA Poly (lactic acid)
AuNP Gold nanoparticle
AgNP Silver nanoparticle
SWCNT Single-walled carbon nanotube
CD Carbon dot
PLGA Poly (lactic co-glycolic acid)
Lf Lactoferrin
UDCA Ursodeoxycholic acid
AZT Azidothymidine
ICAM-1 Intracellular adhesion molecule 1
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